Delivery of neurotrophic factors in the treatment of age-related chronic neurodegenerative diseases

References

• Dobson CM. The amyloid phenomenon and its links with human disease. Cold Spring Harb Perspect Biol. 2017;9:a023648.
   PubMed Web of Science ®Google Scholar
• Neurodegenerative Diseases. 2019 Sept. [cited 2019 Oct 19]. Available from: https://www.niehs.nih.gov/research/supported/health/neurodegenerative/index.cfm.NIH
   Google Scholar
• Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest. 2005;115:1449–1457.
   PubMed Web of Science ®Google Scholar
• Carter CJ. Alzheimer’s disease: A pathogenetic autoimmune disorder caused by herpes simplex in a gene-dependent manner. Int J Alzheimers Dis. 2010;140539.
   PubMedGoogle Scholar
• Mao X, Ou MT, Karuppagounder SS, et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. 2016;353:aah3374.
   PubMed Web of Science ®Google Scholar
• Di Scala C, Chahinian H, Yahi N, et al. Interaction of Alzheimer’s β-amyloid peptides with cholesterol: mechanistic insights into amyloid pore formation. Biochemistry. 2014;53:4489–4502.
   PubMed Web of Science ®Google Scholar
• Briston T, Hicks AR. Mitochondrial dysfunction and neurodegenerative proteinopathies: mechanisms and prospects for therapeutic intervention. Biochem Soc Trans. 2018;46:829–842.
   PubMed Web of Science ®Google Scholar
• Hillen H. The beta amyloid dysfunction (BAD) hypothesis for Alzheimer ’ s disease. Frontiers in Neuroscience. 2019;13:1154.
   Google Scholar
• Gibbs E, Silverman JM, Zhao B, et al. A rationally designed humanized antibody selective for amyloid beta oligomers in Alzheimer’s disease. Sci Rep. 2019;9:1–14.
   PubMed Web of Science ®Google Scholar
• Lewerenz J, Maher P. Chronic glutamate toxicity in neurodegenerative diseases-what is the evidence? Front Neurosci. 2015;9:1–20.
   PubMed Web of Science ®Google Scholar
• Lin -C-C, Edelson BT. New insights into the role of IL-1β in EAE and MS. J Immunol. 2017;198:4553–4560.
   PubMed Web of Science ®Google Scholar
• Walker KA. Inflammation and neurodegeneration: chronicity matters. Aging (Albany NY). 2019;11:3.
   Google Scholar
• Chen WW, Zhang X, Huang WJ. Role of neuroinflammation in neurodegenerative diseases (Review). Mol Med Rep. 2016;13:3391–3396.
   PubMed Web of Science ®Google Scholar
• Herrup K, Carrillo M, Schenk D, et al. Beyond amyloid: getting real about non-amyloid targets in Alzheimer’s disease. Alzheimer’s Dement. 2013;9:452–458.
   PubMed Web of Science ®Google Scholar
• Basisty N, Meyer JG, Schilling B. Protein turnover in aging and longevity. Proteomics. 2018;18:5–6.
   Web of Science ®Google Scholar
• Berson A, Nativio R, Berger SL, et al. Epigenetic regulation in neurodegenerative diseases. Trends Neurosci. 2018;41:587–598.
   PubMed Web of Science ®Google Scholar
• Palomer E, Martín-Segura A, Baliyan S, et al. Aging triggers a repressive chromatin state at Bdnf promoters in hippocampal neurons. Cell Rep. 2016;16:2889–2900.
   PubMed Web of Science ®Google Scholar
• Xu D, Jin T, Zhu H, et al. TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in aging. Cell. 2018;174:1477–1491.e19.
   PubMed Web of Science ®Google Scholar
• Maness LM, Kastin AJ, Weber JT, et al. The neurotrophins and their receptors: structure, function, and neuropathology. Neurosci Biobehav Rev. 1994;18:143–159.
   PubMed Web of Science ®Google Scholar
• Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical Implications. Arch Med Sci. 2015;11:1164–1178.
   PubMed Web of Science ®Google Scholar
• Levi-Montalcini R. The nerve growth factor: thirty-five years later. Biosci Rep. 1987;7:681–699.
   PubMed Web of Science ®Google Scholar
• Ivanisevic L, Saragovi HU. The neurotrophins. In: Abba J. Kastin, editors. Handbook of biologically active peptides (Second edition). Academic Press2006:1639–1646.
   Google Scholar
• Pietrucha-Dutczak M, Amadio M, Govoni S, et al. The role of endogenous neuroprotective mechanisms in the prevention of retinal ganglion cells degeneration. Front Neurosci. 2018;12:834.
   Web of Science ®Google Scholar
• Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci. 2001;2:24–32.
   PubMed Web of Science ®Google Scholar
• Lin LH, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260:1130–1132.
   PubMed Web of Science ®Google Scholar
• Åkerud P, Holm PC, Castelo-Branco G, et al. Persephin-overexpressing neural stem cells regulate the function of nigral dopaminergic neurons and prevent their degeneration in a model of Parkinson’s disease. Mol Cell Neurosci. 2002;21:205–222.
   PubMed Web of Science ®Google Scholar
• Ramer MS, Priestley JV, McMahon SB. Functional regeneration of sensory axons into the adult spinal cord. Nature. 2000;403:312–316.
   PubMed Web of Science ®Google Scholar
• Nielsen J, Gotfryd K, Li S, et al. Role of glial cell line-derived neurotrophic factor (GDNF)-neural cell adhesion molecule (NCAM) interactions in induction of neurite outgrowth and identification of a binding site for NCAM in the heel region of GDNF. J Neurosci. 2009;29:11360–11376.
   PubMed Web of Science ®Google Scholar
• Carnow TB, Manthorpe M, Davis GE, et al. Localized survival of ciliary ganglionic neurons identifies neuronotrophic factor bands on nitrocellulose blots. J Neurosci. 1985;5:1965–1971.
   PubMed Web of Science ®Google Scholar
• Martinou JC, Martinou I, Kato AC. Cholinergic differentiation factor (CDF/LIF) promotes survival of isolated rat embryonic motoneurons in vitro. Neuron. 1992;8:737–744.
   PubMed Web of Science ®Google Scholar
• Fann MJ, Patterson PH. Neuropoietic cytokines and activin A differentially regulate the phenotype of cultured sympathetic neurons. Proc Natl Acad Sci U S A. 1994;91:43–47.
   PubMed Web of Science ®Google Scholar
• Forger NG, Prevette D, DeLapeyrière O, et al. Cardiotrophin-like cytokine/cytokine-like factor 1 is an essential trophic factor for lumbar and facial motoneurons in vivo. J Neurosci. 2003;23:8854–8858.
   PubMed Web of Science ®Google Scholar
• Weiss TW, Samson AL, Niego B, et al. Oncostatin M is a neuroprotective cytokine that inhibits excitotoxic injury in vitro and in vivo. Faseb J. 2006;20:2369–2371.
   PubMed Web of Science ®Google Scholar
• Sobuś A, Machaliński B. Trophic factors in the therapeutic challenge against ALS: current research directions. Updat Amyotroph Lateral Scler. 2016;213:13.
   Google Scholar
• Ruozi B, Belletti D, Bondioli L, et al. Neurotrophic factors and neurodegenerative diseases: a delivery issue. Int Rev Neurobiol. 1st ed. 2012;102:207–247.
   PubMed Web of Science ®Google Scholar
• Costa A, Peppe A, Carlesimo GA, et al. Brain-derived neurotrophic factor serum levels correlate with cognitive performance in Parkinson ’ s disease patients with mild cognitive impairment. Front Behav Neurosci. 2015;9:1–8.
   PubMed Web of Science ®Google Scholar
• Salehi A, Delcroix J, Swaab DF. Alzheimer ’ s disease and NGF signaling. J Neural Transm. 2004;111:323–345.
   PubMed Web of Science ®Google Scholar
• Zhu G, Li J, He L, et al. MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway. Br J Pharmacol. 2015;172:2354–2368.
   PubMed Web of Science ®Google Scholar
• Razgado-Hernandez LF, Espadas-Alvarez AJ, Reyna-Velazquez P, et al. The transfection of BDNF to dopamine neurons potentiates the effect of dopamine D3 receptor agonist recovering the striatal innervation, dendritic spines and motor behavior in an aged rat model of Parkinson’s disease. PLoS One. 2015;10:1–25.
   Web of Science ®Google Scholar
• Baquet ZC, Bickford PC, Jones KR. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci. 2005;25:6251–6259.
   PubMed Web of Science ®Google Scholar
• Baydyuk M, Xu B. BDNF signaling and survival of striatal neurons. Front Cell Neurosci. 2014;8:254.
   PubMed Web of Science ®Google Scholar
• Mitra S, Behbahani H, Eriksdotter M. Innovative therapy for Alzheimer’s disease-with focus on biodelivery of NGF. Front Neurosci. 2019;13:38.
   PubMed Web of Science ®Google Scholar
• Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci U S A. 2002;99:12432–12437.
   PubMed Web of Science ®Google Scholar
• Kromer LF. Nerve growth factor treatment after brain injury prevents neuronal death. Science. 1987;235:214–216.
   PubMed Web of Science ®Google Scholar
• Fischer W, Wictorin K, Björklund A, et al. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature. 1987;329:65–68.
   PubMed Web of Science ®Google Scholar
• Lee WY, Lockniskar MF, Fischer SM. Interleukin-1alpha mediates phorbol ester induced inflammation and epidermal hyperplasia. FASEB. 1994;8:1081–1087.
   PubMed Web of Science ®Google Scholar
• Gu S, Huang H, Bi J, et al. Combined treatment of neurotrophin-3 gene and neural stem cells is ameliorative to behavior recovery of Parkinson ’ s disease rat model. Brain Res. 2008;1257:1–9.
   PubMed Web of Science ®Google Scholar
• Heller A, Price S, Won L. Glial-derived neurotrophic factor (GDNF) induced morphological differentiation of an immortalized monoclonal hybrid dopaminergic cell line of mesencephalic neuronal origin. Brain Res. 1996;725:132–136.
   PubMed Web of Science ®Google Scholar
• Beck KD, Valverde J, Alexi T, et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature. 1995;373:339–341.
   PubMed Web of Science ®Google Scholar
• Arenas E, Trupp M, Åkerud P, et al. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron. 1995;15:1465–1473.
   PubMed Web of Science ®Google Scholar
• Guo Q, Sebastian L, Sopher BL, et al. Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc Natl Acad Sci U S A. 1999;96:4125–4130.
   PubMed Web of Science ®Google Scholar
• Thorne RG, Frey WH. Delivery of neurotrophic factors to the central nervous system. Clin Pharmacokinet. 2001;40:907–946.
   PubMed Web of Science ®Google Scholar
• Turner CA, Watson SJ, Akil H. The fibroblast growth factor family: neuromodulation of affective behavior. Neuron. 2012;76:160–174.
   PubMed Web of Science ®Google Scholar
• Birks JS. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD005593.
   PubMed Web of Science ®Google Scholar
• Schapira AHV. Treatment options in the modern management of Parkinson disease. Arch Neurol. 2007;64:1083–1088.
   PubMed Web of Science ®Google Scholar
• Stanzione PDT. Drugs and clinical trials in neurodegenerative diseases. Ann Ist Super Sanita. 2011;47:49–54.
   PubMed Web of Science ®Google Scholar
• Kennedy ME, Stamford AW, Chen X, et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS b-Amyloid in animal models and in Alzheimer’s disease patients. Sci Transl Med. 2016;8:1–14.
   Web of Science ®Google Scholar
• Kanaan NM, Manfredsson FP. Loss of functional alpha-synuclein: a toxic event in Parkinson’s disease?. J Parkinsons Dis. 2012;2:49–267.
   Google Scholar
• Winblad B, Graf A, Riviere ME, et al. Active immunotherapy options for Alzheimer’s disease. Alzheimer’s Res Ther. 2014;6:1–12.
   PubMed Web of Science ®Google Scholar
• Cooley CB, Ryno LM, Plate L, et al. Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chain. Proc Natl Acad Sci U S A. 2014;111:13046–13051.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Waddington M, et al. Tafamidis for transthyretin familial amyloid polyneuropathy. Neurology. 2012;79:785–792.
   PubMed Web of Science ®Google Scholar
• Feng Y, Wang X. Antioxidant therapies for Alzheimer’s disease. Oxid Med Cell Longev. 2012;2012:1–17.
   PubMed Web of Science ®Google Scholar
• Kornhuber J, Weller M, Schoppmeyer K, et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl. 1994;43:91–104.
   PubMedGoogle Scholar
• Marks WJ, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. Lancet Neurol. 2008;7:400–408.
   PubMed Web of Science ®Google Scholar
• Takeda YS, Xu Q. Neuronal differentiation of human mesenchymal stem cells using exosomes derived from differentiating neuronal cells. PLoS One. 2015;10:e0135111.
   Web of Science ®Google Scholar
• Mazzini L, Gelati M, Profico DC, et al. Results from phase I clinical trial with intraspinal injection of neural stem cells in amyotrophic lateral sclerosis: a long-term outcome. Stem Cells Transl Med. 2019;8:887–897.
   PubMed Web of Science ®Google Scholar
• Kumar P, Moon LDF. Therapeutics targeting Nogo-A hold promise for stroke restoration. CNS Neurol Disord Drug Targets. 2013;12:200–208.
   PubMed Web of Science ®Google Scholar
• Cash D, Easton AC, Mesquita M, et al. GSK249320, a monoclonal antibody against the axon outgrowth inhibition molecule myelin-associated glycoprotein, improves outcome of rodents with experimental stroke. J Neurol Exp Neurosci. 2016;2:28–33.
   PubMedGoogle Scholar
• Almutiri S, Berry M, Logan A, et al. Non-viral-mediated suppression of AMIGO3 promotes disinhibited NT3-mediated regeneration of spinal cord dorsal column axons. Sci Rep. 2018;8:1–15.
   PubMed Web of Science ®Google Scholar
• Levy YS, Gilgun-Sherki Y, Melamed E, et al. Therapeutic potential of neurotrophic factors in neurodegenerative diseases. BioDrugs Mech Targets. 2005;19:97–127.
   PubMed Web of Science ®Google Scholar
• Saragovi HU, Gehring K. Development of pharmacological agents for targeting neurotrophins and their receptors. Trends Pharmacol Sci. 2000;21:93–98.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhou Y, Chen S, et al. Current sustained delivery strategies for the design of local neurotrophic factors in treatment of neurological disorders. Asian J Pharm Sci. 2013;8:269–277.
   Google Scholar
• Bartus RT. Translating the therapeutic potential of neurotrophic factors to clinical ‘proof of concept’: A personal saga achieving a career-long quest. Neurobiol Dis. 2012;48:153–178.
   PubMed Web of Science ®Google Scholar
• Weissmiller AM, Wu C. Current advances in using neurotrophic factors to treat neurodegenerative disorders. Transl Neurodegener. 2012;1:14.
   PubMedGoogle Scholar
• Palmer AM. The role of the blood brain barrier in neurodegenerative disorders and their treatment. J Alzheimer’s Dis. 2011;24:643–656.
   PubMed Web of Science ®Google Scholar
• Nicholson C, Syková E. Extracellular space structure revealed by diffusion analysis. Trends Neurosci. 1998;21:207–215.
   PubMed Web of Science ®Google Scholar
• Yan Q, Matheson C, Sun J, et al. Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression. Exp Neurol. 1994;127:23–36.
   PubMed Web of Science ®Google Scholar
• Davson H, Welch K, Segal MB, et al. The physiology and pathophysiology of the cerebrospinal fluid. New York. Livingstone, I987. Ann Neurol Off J Am Neurol Assoc Child Neurol Soc. 1988;24:106.
   Google Scholar
• Cedarbaum JM, Brooks BR. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology. 1996;46:1244–1249.
   PubMed Web of Science ®Google Scholar
• Boado RJ, Pardridge WM. Comparison of blood-brain barrier transport of Glial-Derived Neurotrophic Factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. Drug Metab Dispos. 2009;37:2299–2304.
   PubMed Web of Science ®Google Scholar
• Krewson CE, Klarman ML, Saltzman WM. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res. 1995;680:196–206.
   PubMed Web of Science ®Google Scholar
• Kroin JS. Intrathecal drug administration present use and future trends. Aust J Hosp Pharm. 1992;22:319–326.
   Google Scholar
• Pawar GN, Parayath NN, Nocera AL, et al. Direct CNS delivery of proteins using thermosensitive liposome-in-gel carrier by heterotopic mucosal engrafting. PLoS One. 2018;13:1–15.
   Web of Science ®Google Scholar
• Alcalá-Barraza SR, Lee MS, Hanson LR, et al. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J Drug Target. 2010;18:179–190.
   PubMed Web of Science ®Google Scholar
• Vaka SRK, Murthy SN, Balaji A, et al. Delivery of brain derived neurotrophic factor via nose to brain pathway. Pharm Res. 2012;29:441–447.
   PubMed Web of Science ®Google Scholar
• Bleier BS, Kohman RE, Feldman RE, et al. Permeabilization of the blood-brain barrier via mucosal engrafting: implications for drug delivery to the brain. PLoS One. 2013;8:1–7.
   Web of Science ®Google Scholar
• Bleier BS, Kohman RE, Guerra K, et al. Heterotopic mucosal grafting enables the delivery of therapeutic neuropeptides across the blood brain barrier. Neurosurgery. 2016;78:448–457.
   PubMedGoogle Scholar
• Angelova A, Angelov B, Drechsler M, et al. Neurotrophin delivery using nanotechnology. Drug Discov Today. 2013;18:1263–1271.
   PubMed Web of Science ®Google Scholar
• Martinez-Fong D, Bannon MJ, Trudeau LE, et al. NTS-Polyplex: A potential nanocarrier for neurotrophic therapy of Parkinson’s disease. Nanomedicine Nanotechnology, Biol Med. 2012;8:1052–1069.
   PubMed Web of Science ®Google Scholar
• Gaffal EB-TE, O’Keeffe M, Tormo D, et al. Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-α production. J Gene Med. 2008;10:610–618.
   PubMedGoogle Scholar
• Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE, et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target. 2009;17:564–574.
   PubMed Web of Science ®Google Scholar
• Huang R, Ke W, Liu Y, et al. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J Neurol Sci. 2010;290:123–130.
   PubMed Web of Science ®Google Scholar
• Mohtaram NK, Montgomery A, Willerth SM. Biomaterial-based drug delivery systems for the controlled release of neurotrophic factors. Biomed Mater. 2013;8:022001.
   PubMed Web of Science ®Google Scholar
• Censi R, Di P, Vermonden T, et al. Hydrogels for protein delivery in tissue engineering. J Control Release. 2012;161:680–692.
   PubMed Web of Science ®Google Scholar
• Ji W, Sun Y, Yang F, et al. Bioactive electrospun scaffolds delivering growth factors and genes for tissue engineering applications. Pharm Res. 2011;28:1259–1272.
   PubMed Web of Science ®Google Scholar
• Valmikinathan CM, Defroda S, Yu X. Polycaprolactone and bovine serum albumin based nanofibers for controlled release of nerve growth factor. Biomacromolecules. 2009;10:1084–1089.
   PubMed Web of Science ®Google Scholar
• Lampe KJ, Kern DS, Mahoney MJ, et al. The administration of BDNF and GDNF to the brain via PLGA microparticles patterned within a degradable PEG-based hydrogel: protein distribution and the glial response. J Biomed Mater Res A. 2011;96:A:595–607.
   PubMedGoogle Scholar
• Han N, Johnson J, Lannutti JJ, et al. Hydrogel – electrospun fi ber composite materials for hydrophilic protein release. J Control Release. 2012;158:165–170.
   PubMed Web of Science ®Google Scholar
• Lindvall O, Odin P. Clinical application of cell transplantation and neurotrophic factors in CNS disorders. Curr Opin Neurobiol. 1994;4:752–757.
   PubMedGoogle Scholar
• Conner JM, Darracq MA, Roberts J, et al. Nontropic actions of neurotrophins: subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation. Proc Natl Acad Sci U S A. 2001;98:1941–1946.
   PubMed Web of Science ®Google Scholar
• Ingusci S, Verlengia G, Soukupova M, et al. Gene therapy tools for brain diseases. Front Pharmacol. 2019;10:1–19.
   PubMed Web of Science ®Google Scholar
• Lykken EA, Shyng C, Edwards RJ, et al. Recent progress and considerations for AAV gene therapies targeting the central nervous system. J Neurodev Disord. 2018;10:1–10.
   PubMed Web of Science ®Google Scholar
• Gray SJ, Woodard KT, Samulski RJ. Viral vectors and delivery strategies for CNS gene therapy. Ther Deliv. 2010;1:517–534.
   PubMedGoogle Scholar
• Hadaczek P, Eberling JL, Pivirotto P, et al. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther. 2010;18:1458–1461.
   PubMed Web of Science ®Google Scholar
• Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science. 2000;290:767–773.
   PubMed Web of Science ®Google Scholar
• Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat Med. 2009;15:331–337.
   PubMed Web of Science ®Google Scholar
• Fouad GI. Stem cells as a promising therapeutic approach for Alzheimer’s disease: a review. Bull Natl Res Cent. 2019;43:52.
   Google Scholar
• Bali P, Lahiri D, Banik A, et al. Potential for stem cells therapy in Alzheimer’s disease: do neurotrophic factors play critical role?. Curr Alzheimer Res. 2017;14:208–220.
   PubMed Web of Science ®Google Scholar
• Mcginley LM, Kashlan ON, Bruno ES, et al. Human neural stem cell transplantation improves cognition in a murine model of Alzheimer ’ s disease. Sci Rep. 2018;8:1–10.
   PubMed Web of Science ®Google Scholar
• Hussain R, Zubair H, Pursell S, et al. Neurodegenerative diseases: regenerative mechanisms and novel therapeutic approaches. Brain Sci. 2018;8:177.
   Web of Science ®Google Scholar
• Adessi C, Soto C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr Med Chem. 2005;9:963–978.
   Google Scholar
• Longo F, Yang T, Knowles J, et al. Small molecule neurotrophin receptor ligands: novel strategies for targeting Alzheimers disease mechanisms. Curr Alzheimer Res. 2007;4:503–506.
   PubMed Web of Science ®Google Scholar
• Massa SM, Rajadas J, Longo FM, et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents find the latest version : technical advance small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest. 2010;120:1774–1785.
   PubMed Web of Science ®Google Scholar
• Wahlestedt C. Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov. 2013;12:433–446.
   PubMed Web of Science ®Google Scholar
• Modarresi F, Faghihi MA, Lopez-toledano MA, et al. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat Biotechnol. 2012;30:453–459.
   PubMed Web of Science ®Google Scholar
• Kiaei M. New hopes and challenges for treatment of neurodegenerative disorders: great opportunities for Young neuroscientists. Basic Clin Neurosci. 2013;4:3–4.
   PubMedGoogle Scholar
• Cuny GD. Neurodegenerative diseases: challenges and opportunities. Future Med Chem. 2012;4:1647–1649.
   PubMed Web of Science ®Google Scholar
• Ransohoff RM. All (animal) models (of neurodegeneration) are wrong. Are they also useful? J Exp Med. 2018;215:2955–2958.
   PubMedGoogle Scholar
• Dawson TM, Golde TE, Lagier-tourenne C. Animal models of neurodegenerative diseases. Nat Neurosci. 2018;21:1370–1379.
   PubMed Web of Science ®Google Scholar
• Blurton-Jones M, LaFerla F. Pathways by which Aβ facilitates tau pathology. Curr Alzheimer Res. 2006;3:437–448.
   PubMedGoogle Scholar
• Sasaguri H, Nilsson P, Hashimoto S, et al. APP mouse models for Alzheimer’s disease preclinical studies. Embo J. 2017;36:2473–2487.
   PubMed Web of Science ®Google Scholar
• Fisher EMC, Bannerman DM. Mouse models of neurodegeneration: know your question, know your mouse. Sci Transl Med. 2019;11:1–16.
   Web of Science ®Google Scholar
• Schmidt N, Schulze J, Warwas DP, et al. Long-term delivery of brain-derived neurotrophic factor (BDNF) from nanoporous silica nanoparticles improves the survival of spiral ganglion neurons in vitro. PLoS One. 2018;13:1–23.
   Web of Science ®Google Scholar
• Hudry E, Vandenberghe LH. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron Elsevier Inc. 2019;101:839–862.
   Google Scholar
• Hinderer C, Katz N, Buza EL, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther. 2018;29:285–298.
   PubMed Web of Science ®Google Scholar
• Goswami R, Subramanian G, Silayeva L, et al. Gene therapy leaves a vicious cycle. Front Oncol. 2019;9:297.
   Web of Science ®Google Scholar
• Schapira AH. Meeting the challenge of neurodegenerative diseases. Neurodegener Dis Manag. 2011;1:1–2.
   Google Scholar
• Ribeiro FM, Camargos ERDS, Souza LCD, et al. Animal models of neurodegenerative diseases. Brazilian J Psychiatry. 2013;35:S82–S91.
   PubMedGoogle Scholar